Statistics for Adjuvant Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors: Is This the Preferred Option?
Total visits
| views | |
|---|---|
| Adjuvant Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors: Is This the Preferred Option? | 73 |
Total visits per month
| views | |
|---|---|
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
File Visits
| views | |
|---|---|
| Einhorn2020Adjuvant.pdf | 159 |
| java.util.UUID:f99aa3aa-c1f0-4504-b5d7-0b1704268338 | 39 |
| java.util.UUID:23a5f8c6-a2fa-40f3-9b95-4bd5f36cd3d8 | 8 |
| java.util.UUID:ad3dd7f5-e450-497b-9aed-8267013cafab | 7 |
Top country views
| views | |
|---|---|
| United States | 59 |
| Canada | 3 |
| China | 2 |
| Japan | 1 |
| Malaysia | 1 |
| Sweden | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 36 |
| Fairfield | 7 |
| Houston | 6 |
| Cambridge | 4 |
| Toronto | 3 |
| Beijing | 2 |
| San Francisco | 2 |
| Ann Arbor | 1 |
| Seremban | 1 |
| Stockholm | 1 |
| Westbury | 1 |